Alumis (ALMS) Competitors $3.28 +0.01 (+0.15%) Closing price 07/3/2025 03:09 PM EasternExtended Trading$3.36 +0.07 (+2.28%) As of 07/3/2025 04:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock ALMS vs. SION, ANAB, NUVB, TRVI, DAWN, STOK, GHRS, SANA, URGN, and AUTLShould you be buying Alumis stock or one of its competitors? The main competitors of Alumis include Sionna Therapeutics (SION), AnaptysBio (ANAB), Nuvation Bio (NUVB), Trevi Therapeutics (TRVI), Day One Biopharmaceuticals (DAWN), Stoke Therapeutics (STOK), GH Research (GHRS), Sana Biotechnology (SANA), Urogen Pharma (URGN), and Autolus Therapeutics (AUTL). These companies are all part of the "pharmaceutical products" industry. Alumis vs. Its Competitors Sionna Therapeutics AnaptysBio Nuvation Bio Trevi Therapeutics Day One Biopharmaceuticals Stoke Therapeutics GH Research Sana Biotechnology Urogen Pharma Autolus Therapeutics Sionna Therapeutics (NASDAQ:SION) and Alumis (NASDAQ:ALMS) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, institutional ownership, risk, earnings, profitability, media sentiment, valuation and analyst recommendations. Does the media prefer SION or ALMS? In the previous week, Sionna Therapeutics had 6 more articles in the media than Alumis. MarketBeat recorded 6 mentions for Sionna Therapeutics and 0 mentions for Alumis. Sionna Therapeutics' average media sentiment score of 1.15 beat Alumis' score of 0.00 indicating that Sionna Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Sionna Therapeutics Positive Alumis Neutral Do analysts rate SION or ALMS? Sionna Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 81.69%. Alumis has a consensus price target of $22.86, indicating a potential upside of 595.80%. Given Alumis' stronger consensus rating and higher possible upside, analysts clearly believe Alumis is more favorable than Sionna Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sionna Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Alumis 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has better valuation & earnings, SION or ALMS? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSionna TherapeuticsN/AN/A-$61.69MN/AN/AAlumisN/AN/A-$294.23MN/AN/A Is SION or ALMS more profitable? Sionna Therapeutics' return on equity of 0.00% beat Alumis' return on equity.Company Net Margins Return on Equity Return on Assets Sionna TherapeuticsN/A N/A N/A Alumis N/A -406.27%-107.29% SummarySionna Therapeutics beats Alumis on 5 of the 9 factors compared between the two stocks. Get Alumis News Delivered to You Automatically Sign up to receive the latest news and ratings for ALMS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ALMS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ALMS vs. The Competition Export to ExcelMetricAlumisMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$184.98M$2.92B$5.56B$9.05BDividend YieldN/A2.44%5.24%3.99%P/E RatioN/A21.5627.6520.23Price / SalesN/A283.26419.56119.26Price / CashN/A41.7026.2128.59Price / Book0.607.538.035.65Net Income-$294.23M-$55.14M$3.18B$249.15M7 Day Performance8.77%4.61%2.93%3.28%1 Month Performance-8.50%0.90%1.72%3.95%1 Year PerformanceN/A5.40%34.39%20.98% Alumis Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ALMSAlumis2.8876 of 5 stars$3.29+0.2%$22.86+595.8%N/A$184.98MN/A0.00N/ASIONSionna TherapeuticsN/A$15.05+1.5%$38.50+155.8%N/A$664.01MN/A0.0035Positive NewsInsider TradeANABAnaptysBio2.286 of 5 stars$22.58-3.4%$42.38+87.7%-2.8%$663.25M$91.28M-4.65100News CoverageInsider TradeNUVBNuvation Bio3.4398 of 5 stars$1.95-1.3%$7.17+268.5%-31.2%$661.81M$7.87M-0.8360TRVITrevi Therapeutics3.2765 of 5 stars$5.61-0.9%$20.29+261.6%+128.5%$659.76MN/A-12.5020News CoverageAnalyst ForecastAnalyst RevisionDAWNDay One Biopharmaceuticals1.7011 of 5 stars$6.41-1.2%$30.57+377.3%-50.4%$649.21M$131.16M-9.0260Upcoming EarningsSTOKStoke Therapeutics4.0255 of 5 stars$11.71-1.1%$23.20+98.1%-12.5%$642.92M$36.56M14.91100News CoverageAnalyst ForecastGHRSGH Research1.5715 of 5 stars$12.34-0.5%$32.00+159.3%+26.9%$641.53MN/A-15.6110News CoverageAnalyst UpgradeSANASana Biotechnology2.7581 of 5 stars$2.83-1.6%$8.60+204.4%-37.2%$636.98MN/A-3.21380Analyst ForecastGap UpURGNUrogen Pharma4.4708 of 5 stars$13.38+2.1%$32.86+145.6%-15.1%$621.10M$90.40M-4.24200AUTLAutolus Therapeutics2.5424 of 5 stars$2.30-0.6%$9.32+306.1%-31.3%$611.86M$10.12M-2.61330 Related Companies and Tools Related Companies SION Alternatives ANAB Alternatives NUVB Alternatives TRVI Alternatives DAWN Alternatives STOK Alternatives GHRS Alternatives SANA Alternatives URGN Alternatives AUTL Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ALMS) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alumis Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Alumis With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
